127 related articles for article (PubMed ID: 36060200)
1. Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America.
van der Zee IT; Vreman RA; Liberti L; Garza MA
Rev Panam Salud Publica; 2022; 46():e115. PubMed ID: 36060200
[TBL] [Abstract][Full Text] [Related]
2. Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries.
Durán CE; Cañás M; Urtasun MA; Elseviers M; Andia T; Vander Stichele R; Christiaens T
Rev Panam Salud Publica; 2021; 45():e10. PubMed ID: 33859678
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications.
Argotti U; Leyens L; Lisbona C; López P; Alonso-Orgaz S; Nevado A; Cozzi V
Ther Innov Regul Sci; 2023 Nov; 57(6):1287-1297. PubMed ID: 37682461
[TBL] [Abstract][Full Text] [Related]
4. Reliance is key to effective access and oversight of medical products in case of public health emergencies.
Saint-Raymond A; Valentin M; Nakashima N; Orphanos N; Santos G; Balkamos G; Azatyan S
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):805-810. PubMed ID: 35945703
[TBL] [Abstract][Full Text] [Related]
5. Cooperation Agreements, Memorandums of Understanding, and Letters of Intent as Instruments to Facilitate the Implementation of Reliance in Latin America.
Rodríguez H; De Lucia ML; Liberti L
Clin Ther; 2022 Aug; 44(8):1107-1128. PubMed ID: 35798570
[TBL] [Abstract][Full Text] [Related]
6. Worldwide Regulatory Reliance: Launching A Pilot on A Chemistry, Manufacturing and Control Post Approval Change for A Vaccine.
Gastineau T; Ban C; Basso A; Brehme F; Silva AL; Faure O; Le Palaire L; Persaud P; Rodriguez H
PDA J Pharm Sci Technol; 2023 Nov; ():. PubMed ID: 37973190
[TBL] [Abstract][Full Text] [Related]
7. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
[TBL] [Abstract][Full Text] [Related]
8. Emergency use authorization of medicines: History and ethical dilemma.
Bishnoi M; Sonker A
Perspect Clin Res; 2023; 14(2):49-55. PubMed ID: 37325578
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Vaccines and Roles of the Health Regulatory Authority in Tunisia.
Chtiba N; Cherif D; Mersni I; Kadri M; Jemei A; Lassoued I; Razgallah Khrouf M
Disaster Med Public Health Prep; 2022 Jul; ():1-3. PubMed ID: 35899949
[TBL] [Abstract][Full Text] [Related]
10. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
[TBL] [Abstract][Full Text] [Related]
11. A Proposal of a Combined Convergence Regulatory Strategy Applied to Post-approval Changes by Latin American Countries, Reducing Workload and Allowing Continuous Improvement to Guarantee the Quality, Safety, and Efficacy of Medicines.
Rodriguez H; De Lucia ML
Front Med (Lausanne); 2021; 8():768376. PubMed ID: 34888329
[TBL] [Abstract][Full Text] [Related]
12. Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study.
Badnjević A; Pokvić LG; Džemić Z; Bečić F
Biomed Eng Online; 2020 Oct; 19(1):75. PubMed ID: 33008462
[TBL] [Abstract][Full Text] [Related]
13. Strengthening vaccination policies in Latin America: an evidence-based approach.
Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
[TBL] [Abstract][Full Text] [Related]
14. Cuba's National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED).
Aguilar-Guerra TL; Fajardo-Díaz EM; Gorry C
MEDICC Rev; 2021; 23(3-4):9-14. PubMed ID: 34516531
[TBL] [Abstract][Full Text] [Related]
15. Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan.
Urushihara H; Matsui S; Kawakami K
Biosecur Bioterror; 2012 Dec; 10(4):372-82. PubMed ID: 23210832
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority: implications for African regulatory authorities.
Danks L; Semete-Makokotlela B; Otwombe K; Parag Y; Walker S; Salek S
Front Med (Lausanne); 2023; 10():1265058. PubMed ID: 37937144
[TBL] [Abstract][Full Text] [Related]
17. Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research.
Abbas N; Babar ZU
J Pharm Policy Pract; 2021 Dec; 14(1):110. PubMed ID: 34952647
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a Framework for an Abridged Review Using Good Reliance Practices: Optimising the Medicine Regulatory Review Process in South Africa.
Keyter A; Salek S; McAuslane N; Banoo S; Azatyan S; Walker S
Ther Innov Regul Sci; 2020 Sep; 54(5):1199-1207. PubMed ID: 32865802
[TBL] [Abstract][Full Text] [Related]
19. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
Dellepiane N; Akanmori BD; Gairola S; Jadhav SS; Parker C; Rodriguez C; Srivastava S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S428-33. PubMed ID: 26553671
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities.
McAuslane N; Bujar M; Sithole T; Ngum N; Owusu-Asante M; Walker S
Pharmaceut Med; 2023 May; 37(3):251-260. PubMed ID: 37074548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
